NCT00174525

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Pharmacology Research Institute · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: —

Summary

This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study. AAB-001 is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). In Alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to remove it.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	AAB-001

Timeline

• Start date: 2005-04-01
• Completion: 2008-04-01
• First posted: 2005-09-15
• Last updated: 2012-05-09

Locations

2 sites across 1 country: United States